Greenfield Medicinal Cannabis is a licensed medicinal cannabis importer and distributor in Australia.

A team of established industry leaders


Our Team

Greenfield MC is its people. It takes the best people to deliver the best product.


Nicholas Hanna 
Chief Executive Officer

Nicholas is a lawyer who specialises in health, drug, and regulatory law, with significant experience in the Australian medicinal cannabis space. He has advised Australian medicinal cannabis businesses and has a wealth of knowledge about regulatory and legal frameworks governing the industry. Nicholas has substantial experience working with the Medical Council of NSW, Health Care Complaints Commission, and various other government departments and regulatory bodies. He has significant personal interests in medicinal cannabis assets in Canada, Colombia, Germany, and the USA.


A/Prof, Dr Sree Appu,
Chief Medical Officer,
Chairman of the Medical Board

Sree is a leading surgical Uro-Oncologist and the recent Clinical Head of Urology for the Monash Cancer Centre. He is the Head  of Southern Urology as well as IMAGENEX, a medical cancer screening service. Sree is also an academic researcher and was appointed Associate Professor in Urology by Monash University in 2012. He has published more than 50 peer reviewed articles in various medical journals and has served as an examiner, international reviewer, and educator. 


Arjun Chhabra
Chairman and President

Arjun is a lawyer who specialises in corporate, drug, health, and regulatory law. He has a background in mergers and acquisitions, capital raisings, and corporate governance. Arjun has worked with start-ups and in emerging markets, having worked as a corporate lawyer in Australia, the Asia-Pacific, and the Middle East, and as an investment banker in sub-Saharan Africa. He has worked with Deloitte, Blake Dawson Waldron (now Ashurst), Baker & McKenzie, Clyde & Co, and was the Chief Executive Officer of Anthesis Capital.


Katy Williams Day
Chief Operating Officer

Katy is a pharmacist with over 20 years of commercial experience in the medical and pharmacological industries. She was the recent head of Product and Regulatory Affairs at an ASX-listed Medicinal Cannabis company, leading efforts around their Australian cultivation, manufacturing, and research operations, and planned expansion into New Zealand and Asia. Katy has previously held positions as head of medical affairs, head of regulatory and scientific affairs, director of regulatory affairs, and quality and compliance. She has worked at Merck Serono, Phebra, Sandoz, Pfizer, and Genzyme Australasia (a Sanofi company). She has extensive experience in the launch and commercialisation of new drugs and products, as well as overseeing clinical research trials. Katy is a member of various industry bodies, including Medicinal Cannabis Industry Australia’s Regulatory Affairs and Standards Group, and their Policy and Legislative Affairs Working Group.


Sandip Manku
Pharmaceutical and
Risk Compliance Officer  

Sandip is a registered Australian Pharmacist and a Member of the Society of Hospitals Pharmacists Australia. He has worked in the pharmaceutical industry for over 20 years in various Sales and Management roles in Roche Australia, Pfizer Australia, Sandoz Australia, and Hospira Australia. Sandip has owned and operated a pharmacy and founded a specialist pharmaceutical wholesaler and importer which focuses on hospital pharmaceuticals and orphan drugs.


Janja Diana Jelic
Patient and Doctor Relations

Janja is a registered pharmacist and Member of the Australian Association of Consultant Pharmacy (AACP). She has worked in the industry for over 15 years in various consulting and advisory roles. For the last 10 years Janja has provided personalised Medication Management Reviews for people living in the community and aged care facilities, working closely with their general practitioners to optimise medication use and health outcomes. Janja's experience in the medicinal cannabis industry and issues concerning patient access commenced when she worked through the regime to source medical grade products for an immediate family member. She has previously been a Director and Principal Pharmacist for Vanguard Medication Consultants, and Senior Consultant Pharmacist for Meditrax Medication Management Specialists. 


Ivon Diaz 
Quality Control Officer 

Ivon has worked in global pharmaceutical and health companies for 14 years in Colombia, Australia, and the United Kingdom. Most recently she has worked in the UK with Reckitt Benckiser as the Health Hub Quality Commercial Manager, and in their Australian subsidiary as the New Product Implementation Manager Australia and New Zealand, as well as Senior Quality Compliance Coordinator Australia and New Zealand. In Colombia, Ivon worked with Biochem Farmaceutica de Colombia as a New Product Development and Regulatory Affairs Associate, and prior to that with Schering AG (now Bayer AG) as a Quality Control and Quality Assurance Associate.


Meilani Humphreys
Sales and
Distribution Officer 

Meilani has worked in global pharmaceutical companies for over 15 years. She has worked at Roche Australia, Pfizer Australia, and Nutricia Australia. Meilani has held several sales and distribution roles and worked in new business development. Her previous positions have included Pharmaceutical Sales Officer, Hospital and Medical Clinic Specialist, Medical Devices Territory Manager, and Senior Relationship Officer. Meilani brings a wealth of experience in launching new pharmaceutical products.


Anthony George
Financial Officer

Anthony is a Chartered Accountant and Registered Tax Agent with nearly 20 years experience working in the Finance team at Pfizer Australia. At Pfizer Australia he held the following positions: Head of Finance Operations Australia and New Zealand; Company Secretary; Finance Manager; Financial Services Manager, Financial Controller, and Chief Accountant. Anthony has significant experience in corporate governance, business development, and mergers and acquisitions. Prior to joining Pfizer Australia, Anthony worked at Touche Tohmatsu (now Deloitte). 


A/Prof, Dr Sree Appu,
Chief Medical Officer,
Chairman of the Medical Board

Sree is a leading surgical Uro-Oncologist and the recent Clinical Head of Urology for the Monash Cancer Centre. He is the Head  of Southern Urology as well as IMAGENEX, a medical cancer screening service. Sree is also an academic researcher and was appointed Associate Professor in Urology by Monash University in 2012. He has published more than 50 peer reviewed articles in various medical journals and has served as an examiner, international reviewer, and educator. 


Prof. Robert Iansek 

Robert is a Professor of Geriatric Neurology at Monash University, as well as the Director of the Clinical Research Centre for Movement Disorders & Gait and Director of the Victorian Comprehensive Parkinson’s Program at Kingston Centre, Southern Health. In 2013 he was awarded the Order of Australia, the country’s highest honour, for services to medicine in the field of neurology. Robert has published over 200 articles in peer-reviewed journals, edited three books, and has contributed chapters to multiple other publications.


Associate Prof. Ajeet Singh
MB.BS(Melo) M.Psych., FRANZCP, MD 

Ajeet is a Psychiatrist and Pharmacogeneticist, as well as an Adjunct Associate Professor at Deakin Medical School. He is the founder of CNSDose, a US and Australian genetic testing company that analyses  patients’ brains to provide medication guidance for Geriatrics, Primary Care, Neurology, Internal Medicine, and Psychiatry. Ajeet has worked with Barwon Health, the Geelong Hospital and Clinic, The Alfred Hospital, Latrobe Regional Hospital, and the Thomas Embling Forensic Psychiatry Hospital. 


Dr Ben Barresi

Ben is a GP specialised in sports medicine and addiction medicine. He has held key positions in the Australian Football League (AFL) as a team physician, primarily at the Carlton Football Club, and is presently the Greater Western Sydney Giants match day doctor for their Victorian fixtures. Ben also provides GP liaison support for admitting treating psychiatrists who manage inpatients at the substance disorders programs at The Melbourne Clinic. He is presently a medical advisor to WorkSafe Victoria, the Transport Accident Commission, and Comcare, primarily conducting clinical panel reviews for patients who are at high risk of pharmaceutical morbidity. Ben was involved in the key AFL research studies for shoulder instability, hamstring injuries, and concussion.


Dr Dharshi Karalapillai

Dharshi is an ICU Specialist and Anaesthetist and has worked with Austin Hospital, Peter Macallum Hospital, Royal Melbourne Hospital, and the Royal Women’s Hospital. He is a PhD candidate in the field of Perioperative Respiratory Care, due to complete in 2019, that involves a large randomised controlled trial of 1,240 patients. Dharshi has authored numerous research papers and articles in peer-reviewed journals and publications. 


John Latham 

John is a leading figure in the Australian pharmaceutical industry. He was the Managing Director and Chairman of Pfizer Australia from 2007 to 2012. Prior to that he was the Country Manager of Pfizer Singapore and Country Manager of Pfizer Malaysia. He was previously at Bristol-Myers Squibb as the Regional Finance Director Asia, Middle East & Africa, variously located between Princeton, New Jersey and Brussels. Before entering the pharmaceutical industry, he worked at PricewaterhouseCoopers in their Jakarta, Toronto, and Sydney offices.


Dr Adam Pirie

Adam is the Director of Operations at ABcann Australia, a wholly-owned Subsidiary of VIVO Cannabis Inc, a publicly traded medicinal cannabis company listed on the Toronto Stock Exchange. He completed his PhD at the University of Tasmania building and managing a pre-clinical bio-prospecting program which discovered novel plant-derived compounds and therapies to treat type II diabetes, cardiovascular disease, metabolic syndrome and vascular dysfunction. Adam has experience spanning the commercial, scientific and project management activities needed for successful commercialisation of early stage biotechnology.


Moz Ali 

Moz is a senior investment banker with over 20 years of financial services industry experience including advisory roles in Australia, UK, Europe, Asia and South Africa. His transaction experience spans mergers and acquisitions, equity and debt issuance, capital management, structuring and acquisition financing. Moz has worked with Deutsche Bank, Citi, and Tilinghast. Moz’s experience in the healthcare sector includes leading a debt capital raising for Primary Health Care and more recently as part of the team advising the Australian Federal Government on the $5.7 billion privatisation and IPO of Medibank Private. He is currently the Managing Partner of Theorem Consulting.


Tristan Hyodo  

Tristan is the Chief Executive Officer of MC Therapeutics Pty Ltd, a Queensland-based medicinal cannabis cultivator.  He has a background in the health supplements, nutraceuticals, and wellbeing markets. Tristan has held research, quality control, and product development roles in the FMCG industry, and worked for several years at Australia’s largest health food company.